JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.85B |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.5B |
| 3 |
JPMorgan BetaBuilders Canada ETF
BBCA
|
+$1.21B |
| 4 |
Chevron
CVX
|
+$1.08B |
| 5 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$986M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$3.61B |
| 2 |
Occidental Petroleum
OXY
|
+$1.36B |
| 3 |
Merck
MRK
|
+$913M |
| 4 |
Visa
V
|
+$801M |
| 5 |
AT&T
T
|
+$771M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.95% |
| 2 | Technology | 12.9% |
| 3 | Financials | 12.36% |
| 4 | Healthcare | 9.31% |
| 5 | Consumer Discretionary | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5101
Oak Valley Bancorp
OVLY
$287M
| $36K | ﹤0.01% |
1,880
+75
| +4% | +$1.44K |
2018 Q2
4 quarters
|
|
|
SAGE
5102
CALL
DELISTED
Sage Therapeutics
SAGE
| $36K | ﹤0.01% |
200
-334,800
| -100% | -$57.1M |
2019 Q1
1 quarter
|
|
|
CALA
5103
DELISTED
Calithera Biosciences, Inc
CALA
| $36K | ﹤0.01% |
473
-98
| -17% | -$11.1K |
2017 Q4
6 quarters
|
|
5104
Colony Bankcorp
CBAN
$433M
| $35K | ﹤0.01% |
2,040
+2,005
| +5,729% | +$34.2K |
2019 Q1
1 quarter
|
|
5105
Celcuity
CELC
$3.45B
| $35K | ﹤0.01% |
1,616
+198
| +14% | +$4.36K |
2017 Q4
6 quarters
|
|
5106
WisdomTree International Hedged Quality Dividend Growth Fund
IHDG
$2.09B
| $35K | ﹤0.01% |
1,087
+670
| +161% | +$21.8K |
2019 Q1
1 quarter
|
|
5107
Peoples Bancorp of North Carolina
PEBK
$234M
| $35K | ﹤0.01% |
1,264
+131
| +12% | +$3.62K |
2017 Q4
6 quarters
|
|
|
SRT
5108
DELISTED
Startek Inc.
SRT
| $35K | ﹤0.01% |
+4,464
| New | +$34.1K |
2019 Q2
0 quarters
|
|
|
AMRS
5109
DELISTED
Amyris Inc.
AMRS
| $35K | ﹤0.01% |
10,232
+2,223
| +28% | +$8.75K |
2018 Q1
5 quarters
|
|
5110
Invesco China Technology ETF
CQQQ
$2.53B
| $34K | ﹤0.01% |
759
-6,462
| -89% | -$304K |
2018 Q3
3 quarters
|
|
5111
Civeo
CVEO
$341M
| $34K | ﹤0.01% |
+1,758
| New | +$38K |
2019 Q2
0 quarters
|
|
5112
LiveOne
LVO
$37.3M
| $34K | ﹤0.01% |
811
+92
| +13% | +$4.06K |
2018 Q2
4 quarters
|
|
5113
Ponce Financial Group
PDLB
$492M
| $34K | ﹤0.01% |
3,359
+368
| +12% | +$3.75K |
2018 Q2
4 quarters
|
|
5114
Verrica Pharmaceuticals
VRCA
$73.2M
| $34K | ﹤0.01% |
354
+93
| +36% | +$8.72K |
2018 Q3
3 quarters
|
|
5115
PUT
NCR Voyix
VYX
$961M
| $34K | ﹤0.01% |
+1,793
| New | +$33.3K |
2019 Q2
0 quarters
|
|
5116
XBiotech
XBIT
$66.8M
| $34K | ﹤0.01% |
+4,589
| New | +$39.9K |
2019 Q2
0 quarters
|
|
|
EVLO
5117
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $34K | ﹤0.01% |
189
+21
| +13% | +$3.4K |
2018 Q2
4 quarters
|
|
|
CEL
5118
DELISTED
Cellcom Israel, Ltd.
CEL
| $34K | ﹤0.01% |
+11,603
| New | +$44.8K |
2019 Q2
0 quarters
|
|
5119
Ardelyx
ARDX
$865M
| $33K | ﹤0.01% |
12,954
+2,289
| +21% | +$6.89K |
2017 Q3
7 quarters
|
|
5120
Coastal Financial
CCB
$612M
| $33K | ﹤0.01% |
2,132
+217
| +11% | +$3.53K |
2018 Q3
3 quarters
|
|
5121
Cibus
CBUS
$128M
| $33K | ﹤0.01% |
51
+12
| +31% | +$8.94K |
2017 Q4
6 quarters
|
|
5122
Precision BioSciences
DTIL
$168M
| $33K | ﹤0.01% |
84
-1,249
| -94% | -$503K |
2019 Q1
1 quarter
|
|
5123
Escalade
ESCA
$262M
| $33K | ﹤0.01% |
2,940
+341
| +13% | +$3.94K |
2017 Q4
6 quarters
|
|
5124
First Trust Capital Strength ETF
FTCS
$7.41B
| $33K | ﹤0.01% |
+591
| New | +$32.6K |
2019 Q2
0 quarters
|
|
5125
Global Water Resources
GWRS
$230M
| $33K | ﹤0.01% |
3,240
+601
| +23% | +$5.9K |
2017 Q4
6 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2019 Portfolio in Review
As of Q2 2019, JP Morgan Chase held 6,226 positions worth $511B, up 4.5% from $490B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q2 2019 filing shows 458 new, 2,668 increased, 2,116 reduced and 420 closed positions. Its largest new stake was Corteva: 13,119,143 shares worth $388M. The largest sale was iShares 1-3 Year Treasury Bond ETF, an estimated $3.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, up from 27% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2019 buy was Corteva: 13,119,143 shares worth $388M.
- JP Morgan Chase added most to iShares 0-1 Year Treasury Bond ETF in Q2 2019, an estimated $3.85B increase.
- JP Morgan Chase's biggest Q2 2019 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $3.61B.
- JP Morgan Chase fully exited Goldcorp Inc in Q2 2019, selling an estimated $131M.
- JP Morgan Chase's ten largest holdings make up 16% of its $511B portfolio in Q2 2019.
- JP Morgan Chase opened 458 new positions and closed 420 in Q2 2019.
- JP Morgan Chase's portfolio value rose 4.5% quarter-over-quarter to $511B.
Based on JP Morgan Chase's 13F filing for Q2 2019, filed 7 Aug 2019.